Abstract
Mitochondrial calcium uniporter (MCU) has an important role in regulating mitochondrial calcium (Ca<sup>2+</sup>) homeostasis. Dysregulation of mitochondrial Ca<sup>2+</sup> homeostasis has been implicated in various cancers. However, it remains unclear whether MCU regulates mitochondrial Ca<sup>2+</sup> uptake to promote cell growth in colorectal cancer (CRC). Therefore, in the present study the expression of MCU in CRC tissues and its clinical significance were examined. Following which, the biological function of MCU-mediated mitochondrial Ca<sup>2+</sup> uptake in CRC cell growth and the underlying mechanisms were systematically evaluated using in in vitro and in vivo assays, which included western blotting, cell viability and apoptosis assays, as well as xenograft nude mice models. Our results demonstrated that MCU was markedly upregulated in CRC tissues at both the mRNA and protein levels. Upregulated MCU was associated with poor prognosis in patients with CRC. Our data reported that upregulation of MCU enhanced the mitochondrial Ca<sup>2+</sup> uptake to promote mitochondrial biogenesis, which in turn facilitated CRC cell growth in vitro and in vivo. In terms of the underlying mechanism, it was identified that MCU-mediated mitochondrial Ca<sup>2+</sup> uptake inhibited the phosphorylation of transcription factor A, mitochondrial (TFAM), and thus enhanced its stability to promote mitochondrial biogenesis. Furthermore, our data indicated that increased mitochondrial Ca<sup>2+</sup> uptake led to increased mitochondrial production of ROS via the upregulation of mitochondrial biogenesis, which subsequently activated NF-κB signaling to accelerate CRC growth. In conclusion, the results indicated that MCU-induced mitochondrial Ca<sup>2+</sup> uptake promotes mitochondrial biogenesis by suppressing phosphorylation of TFAM, thus contributing to CRC cell growth. Our findings reveal a novel mechanism underlying mitochondrial Ca<sup>2+</sup>-mediated CRC cell growth and may provide a potential pharmacological target for CRC treatment.
Introduction
Colorectal cancer (CRC) remains one of the leading causes of cancer-related deaths worldwide. While researchers know that intracellular calcium ($Ca^{2+}$) signaling is often hijacked by cancer cells to promote survival and metastasis, the specific role of mitochondrial calcium uptake—and the machinery governing it—has been less clear in the context of CRC. This study investigates the Mitochondrial Calcium Uniporter (MCU), the primary pore responsible for $Ca^{2+}$ entry into the mitochondrial matrix, and its functional role in CRC progression.
Methods
The study employed a comprehensive "bench-to-bedside" approach:
- Clinical Validation: Analysis of MCU expression in 203 paired CRC and normal tissue samples using RT-qPCR, Western blotting, and immunohistochemistry (IHC). TCGA data was used to correlate expression with patient survival.
- Cellular Engineering: Stable CRC cell lines (LS174T and HCT-8) were created with either MCU knockdown (via shRNA) or overexpression.
- Functional Assays: Mitochondrial $Ca^{2+}$ levels were measured using the fluorescent sensor MitoPericam. Cell viability (MTS), proliferation (EdU), and apoptosis were assessed.
- Mechanistic Probing: Site-directed mutagenesis on TFAM (Transcription Factor A, Mitochondrial) at specific serine residues (Ser-55, -160, -170) was performed to study its phosphorylation and stability.
- In Vivo Models: Xenograft nude mice were used to observe how modulating MCU and mitochondrial $Ca^{2+}$ (using the buffer parvalbumin) affected tumor growth.
Key Results
The researchers found that MCU acts as a metabolic rheostat; by driving calcium into the mitochondria, it stabilizes the transcription factor TFAM, triggering a wave of mitochondrial biogenesis and ROS-dependent signaling that accelerates tumor growth.
- Upregulation and Prognosis: MCU was markedly upregulated in 78% of CRC tissues compared to normal tissues. Patients with high MCU expression had significantly shorter survival times (log-rank $P = 0.011$).
- The TFAM Stability Switch: Mitochondrial $Ca^{2+}$ uptake inhibits the phosphorylation of TFAM at Serine-55. Normally, phosphorylation targets TFAM for degradation; by preventing this, MCU increases TFAM levels, which in turn increases mitochondrial DNA (mtDNA) copy numbers and overall mitochondrial mass.
- Biogenesis Drives ROS and NF-κB: The increase in mitochondrial biogenesis leads to a controlled increase in ROS production. This mitochondrial-derived ROS acts as a signaling molecule to activate the NF-κB pathway, a well-known driver of cell proliferation and tumor growth.
- In Vivo Validation: In mouse models, MCU-overexpressing tumors grew significantly faster. This growth was reversed by treating the mice with PV-Mito (a mitochondrial $Ca^{2+}$ buffer) or by knocking down TFAM, proving that the $Ca^{2+}$-TFAM axis is the primary driver.
Discussion
While the study clearly identifies the MCU-TFAM-NF-κB axis, the specific phosphatase responsible for TFAM dephosphorylation remains to be definitively identified (candidates like PP2A are suggested). Additionally, the context specificity of MCU—why it promotes growth in CRC rather than triggering $Ca^{2+}$-overload-induced apoptosis—requires further investigation. From a therapeutic perspective, developing "drug-like" small molecules to safely target MCU in patients is a major future hurdle, as current inhibitors like Ru360 have poor bioavailability.
In conclusion, MCU-induced mitochondrial $Ca^{2+}$ uptake promotes mitochondrial biogenesis by suppressing TFAM phosphorylation, contributing significantly to CRC cell growth and providing a potential pharmacological target.
Summary updated